Effects of Factor Ⅻ Polymorphism on the coagulation and fibrinolysis in patients with venous thrombosis

Abstract

Abstract: Objective　To investigate the influence of factor Ⅻ(FⅫ) polymorphism on the coagulation and fibrinolysis in patients with venous thrombosis. Methods　The activity of plasma factor Ⅻ（FⅫ∶C）, fibrinogen（FIB）, D-dimer（D-D）, factor Ⅷ（FⅧ∶C）, von Willabrand factor（VWF）, the activity of plasminogen（PLG∶A）, the activity of plasma antithrombin（AT∶A） and the activity of protein C（PC∶A）were measured by onestage recalcification clotting time assay, immunoturbidimetry assay and chromogenic substrate method in 75 patients with venous thrombosis and 60 healthy controls. The 46th basyl polymorphism at promoter regions in FⅫ gene was analyzed by direct sequencing. Results　The rate of 46TT polymorphism in patients with venous thrombosis was higher than that in control group, and the FⅫ∶C of the 46TT patients was obviously lower than those of the 46CT and 46CC patients and control group（P<0.05）. In 46TT group， AT∶A was lower than that in control group，but the FIB, D-D, FⅧ∶C and VWF were higher（P<0.05）. There were no significant differences in above parameters among the various FⅫ polymorphism groups with venous thrombosis（P>0.05）, and there were also no differences in PLG∶A and PC∶A among these groups（P>0.05）. Conclusions　The FⅫ gene 46TT polymorphism is obviously increased in patients with venous thrombosis, and it will cause the decreasing of FⅫ. There are no statistical significances in the parameters of the coagulation and fibrinolysis at each FⅫ polymorphism group with venous thrombosis.

Key words: Factor Ⅻ, Gene polymorphism, Coagulation, Fibrinolysis, Venous thrombosis

XIE Yaosheng;XIE Haixiao;WANG Mingshan;NIU Zhenzhen;JIN Yanhui. Effects of Factor Ⅻ Polymorphism on the coagulation and fibrinolysis in patients with venous thrombosis[J]. , 2012, 27(3): 213-216.

References

［1］Ho CH，Chau WK, Hsu HC, et al.Causes of venous thrombosis in fifty Chinese patients ［J］.Am J Hematol，2000，63(2)：74-78.

［2］Tirado I， Soria JM， Mateo J，et al. Association after linkage analysis indicates that homozygosity for the 46C->T polymorphism in the F12 gene is a genetic risk factor for venous thrombosis［J］.Thromb Haemost，2004，91(5):899-904.

［3］Colman RW. Biologic activities of the contact factors in vivo-potentiation of hypotension， inflammation， and fibrinolysis， and inhibition of cell adhesion， angiogenesis and thrombosis［J］. Thromb Haemost, 1999， 82(6): 1568-1577.

［4］Kanaji T， Okamura T， Osaki K， et al. A common genetic polymorphism (46C to T substitution) in the 5′-untranslated region of the coagulation factor Ⅻ gene is associated with low translation efficiency and decrease plasma factor Ⅻ level［J］. Blood， 1998， 91(6): 2010-2014.

［5］Zito F， Lowe GD， Rumley A， et al. Association of the factor Ⅻ 46 C>T polymorphism with risk of coronary heart disease (CHD)in the WOSCOPS study［J］.Atherosclerosis，2002，165(1)：153-158.

［6］Tirado I， Fontcuberta J， Soria JM. Rapid detection of the 46C->T polymorphism in the factor Ⅻ gene， a novel genetic risk factor for thrombosis, by melting peak analysis using fluorescence hybridization probes［J］. Genet Test， 2003，7(4)：295-301.

［7］张　玲，于艳辉，吴山力，等. 中国人群FⅫ46C／T多态性与血栓形成关联性解析［J］. 中国实验诊断学，2008，12(11)：1383-1387.

［8］周运恒，王鸿利.凝血因子Ⅻ与纤维蛋白溶解的关系［J］.医学综述，2002，8(4)：223-224.

［9］Endler G， Exner M， Mannhalter C，et al. A common C->T polymorphism at nt 46 in the promoter region of coagulation factor Ⅻ is associated with decreased factor Ⅻ activity［J］. Thromb Res， 2001， 101(4):255-260.

[1]	SHI Shaoxin, CHEN Xueting, XU Xiaofeng, LU Renquan, GUO Lin, ZHUANG Yihui. Role of coagulation function in bacterial bloodstream infection among malignant tumor patients [J]. Laboratory Medicine, 2025, 40(8): 804-809.
[2]	JIANG Fengying, JIANG Yun, MI Rui, QIAN Ximing, WANG Qiubo. Changes of platelet and coagulation function indicators in elderly patients with diabetic foot ulcers [J]. Laboratory Medicine, 2025, 40(7): 708-712.
[3]	YANG Qi, LIN Ying, GUO Nan, LI Xiaobin, SHANG E, LI Hongmin, YAO Xingwei. Changes of coagulation function in elderly patients with severe pneumonia infected by different Gram-negative bacteria [J]. Laboratory Medicine, 2025, 40(6): 560-564.
[4]	WANG Chengyun, GU Ping, PAN Qiuhui, WANG Jing. Changes and clinical value of blood coagulation indexes in children with infection [J]. Laboratory Medicine, 2025, 40(2): 178-181.
[5]	XU Fei, CHEN Zhujun, YU Liang, ZHANG Jing, LU Renquan, GUO Lin, ZHUANG Yihui. Analysis of etiological characteristics and death risk factors of candidemia in tumor patients [J]. Laboratory Medicine, 2024, 39(9): 888-894.
[6]	LIU Yadong, YANG Lei, SONG Shaoting, DU Xiong, LIU Qiang, SUN Jianrong. Correlation between Lp-PLA2 gene polymorphism and histopathological staining of carotid plaque [J]. Laboratory Medicine, 2024, 39(7): 621-626.
[7]	ZHAO Chunhe, SHAO Huihui, CUI Weiqi, XIA Wei, QU Linlin. Progress in application of blood coagulation point-of-care testing [J]. Laboratory Medicine, 2024, 39(7): 709-714.
[8]	ZHAO Qian, ZENG Limin, ZHOU Liping, QI Lin. Relationship between CYP2C19 polymorphism and miR-374b-5p with neurological impairment and short-term prognosis in patients with acute cerebral infarction [J]. Laboratory Medicine, 2024, 39(6): 536-541.
[9]	ZHAO Ying, LU Loukaiyi, DAI Sijia, CHEN Yisheng. Correlation between MTHFR C677T polymorphism and insulin resistance in patients with polycystic ovary syndrome [J]. Laboratory Medicine, 2024, 39(6): 562-567.
[10]	JIANG Jingjing, GU Ping, WANG Chengyun, ZHANG Fan, SHEN Huiying, PAN Qiuhui, WANG Jing. Changes and clinical significance of procalcitonin and coagulation function indicators in children with sepsis [J]. Laboratory Medicine, 2024, 39(6): 573-577.
[11]	LUO Lili, LIU Xiaohui, HAO Jianjun, WANG Lili, LUO Jiao, CHEN Qimei. Efficiency of serum homocysteine，BNP and fibrinogen for deep venous thrombosis of lower extremity after cesarean section [J]. Laboratory Medicine, 2024, 39(3): 277-281.
[12]	SHEN Jinjin, XUE Han, LI Jinfu, GAO Lifei, ZHENG Yehuan. Research progress on the factors of CYP2D6 genotyping [J]. Laboratory Medicine, 2024, 39(3): 291-297.
[13]	WU Shaohua, XI Junnan, LIU Liang, WU Yating, ZHANG Meng, CHEN Liwei, XUE Meng, LIU Shifu. Prognostic roles of Lp-PLA2，HDAC3 and TAFI levels in patients with large-scale cerebral infarction [J]. Laboratory Medicine, 2024, 39(11): 1091-1096.
[14]	CUI Weiqi, OU Xinyang, ZHAO Chunhe, XIA Wei, QU Linlin. Progress of thrombin-activatable fibrinolysis inhibitor determination in clinical application [J]. Laboratory Medicine, 2024, 39(10): 1021-1026.
[15]	LAI Yuanyuan, HE Zhenye, SHEN Huaqing, LIN Yiteng, LIU Xijun, QI Jun, LIN Yongping. Roles of TAT，PIC and thromboelastography for assessing coagulation function in tumor patients [J]. Laboratory Medicine, 2024, 39(1): 43-46.